These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 35128787)
1. Anhydrous Nucleic Acid Nanoparticles for Storage and Handling at Broad Range of Temperatures. Tran AN; Chandler M; Halman J; Beasock D; Fessler A; McKeough RQ; Lam PA; Furr DP; Wang J; Cedrone E; Dobrovolskaia MA; Dokholyan NV; Trammell SR; Afonin KA Small; 2022 Apr; 18(13):e2104814. PubMed ID: 35128787 [TBL] [Abstract][Full Text] [Related]
2. The Application of Light-Assisted Drying to the Thermal Stabilization of Nucleic Acid Nanoparticles. Anh Lam P; Furr DP; Tran A; McKeough RQ; Beasock D; Chandler M; Afonin KA; Trammell SR Biopreserv Biobank; 2022 Oct; 20(5):451-460. PubMed ID: 36067075 [No Abstract] [Full Text] [Related]
3. Light-Assisted Drying for the Thermal Stabilization of Nucleic Acid Nanoparticles and Other Biologics. Trammell SR Methods Mol Biol; 2023; 2709():117-130. PubMed ID: 37572276 [TBL] [Abstract][Full Text] [Related]
4. Exosomes as natural delivery carriers for programmable therapeutic nucleic acid nanoparticles (NANPs). Ke W; Afonin KA Adv Drug Deliv Rev; 2021 Sep; 176():113835. PubMed ID: 34144087 [TBL] [Abstract][Full Text] [Related]
5. Nucleic acid nanoparticles (NANPs) as molecular tools to direct desirable and avoid undesirable immunological effects. Johnson MB; Chandler M; Afonin KA Adv Drug Deliv Rev; 2021 Jun; 173():427-438. PubMed ID: 33857556 [TBL] [Abstract][Full Text] [Related]
6. Exosome mediated delivery of functional nucleic acid nanoparticles (NANPs). Nordmeier S; Ke W; Afonin KA; Portnoy V Nanomedicine; 2020 Nov; 30():102285. PubMed ID: 32781137 [TBL] [Abstract][Full Text] [Related]
7. Break to Build: Isothermal Assembly of Nucleic Acid Nanoparticles (NANPs) Beasock D; Ha A; Halman J; Panigaj M; Wang J; Dokholyan NV; Afonin KA Bioconjug Chem; 2023 Jun; 34(6):1139-1146. PubMed ID: 37293781 [TBL] [Abstract][Full Text] [Related]
8. A cationic amphiphilic co-polymer as a carrier of nucleic acid nanoparticles (Nanps) for controlled gene silencing, immunostimulation, and biodistribution. Halman JR; Kim KT; Gwak SJ; Pace R; Johnson MB; Chandler MR; Rackley L; Viard M; Marriott I; Lee JS; Afonin KA Nanomedicine; 2020 Jan; 23():102094. PubMed ID: 31669854 [TBL] [Abstract][Full Text] [Related]
9. Critical review of nucleic acid nanotechnology to identify gaps and inform a strategy for accelerated clinical translation. Afonin KA; Dobrovolskaia MA; Ke W; Grodzinski P; Bathe M Adv Drug Deliv Rev; 2022 Feb; 181():114081. PubMed ID: 34915069 [TBL] [Abstract][Full Text] [Related]
10. Assessment of Intracellular Compartmentalization of RNA Nanostructures. Radwan Y; Afonin KA; Johnson MB Methods Mol Biol; 2023; 2709():211-228. PubMed ID: 37572283 [TBL] [Abstract][Full Text] [Related]
11. Artificial Immune Cell, AI-cell, a New Tool to Predict Interferon Production by Peripheral Blood Monocytes in Response to Nucleic Acid Nanoparticles. Chandler M; Jain S; Halman J; Hong E; Dobrovolskaia MA; Zakharov AV; Afonin KA Small; 2022 Nov; 18(46):e2204941. PubMed ID: 36216772 [TBL] [Abstract][Full Text] [Related]
12. Toll-Like Receptor-Mediated Recognition of Nucleic Acid Nanoparticles (NANPs) in Human Primary Blood Cells. Hong E; Halman JR; Shah A; Cedrone E; Truong N; Afonin KA; Dobrovolskaia MA Molecules; 2019 Mar; 24(6):. PubMed ID: 30897721 [TBL] [Abstract][Full Text] [Related]
13. Induction of Cytokines by Nucleic Acid Nanoparticles (NANPs) Depends on the Type of Delivery Carrier. Avila YI; Chandler M; Cedrone E; Newton HS; Richardson M; Xu J; Clogston JD; Liptrott NJ; Afonin KA; Dobrovolskaia MA Molecules; 2021 Jan; 26(3):. PubMed ID: 33513786 [TBL] [Abstract][Full Text] [Related]
14. Opportunities, Barriers, and a Strategy for Overcoming Translational Challenges to Therapeutic Nucleic Acid Nanotechnology. Afonin KA; Dobrovolskaia MA; Church G; Bathe M ACS Nano; 2020 Aug; 14(8):9221-9227. PubMed ID: 32706238 [TBL] [Abstract][Full Text] [Related]